---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-006461"
form_type: "8-K"
ticker: "SRTS"
cik: "0001494891"
company_name: "Sensus Healthcare, Inc."
filed_at: "2022-02-10T23:59:59+00:00"
generated_at: "2026-06-27T09:10:18.623094+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensus Healthcare Q4 record revenue $13.0M, EPS $0.32; FY 2021 revenue $27.0M up 182%

## Summary
- Q4 revenue $13.0M (+156% YoY); net income $5.3M ($0.32 diluted EPS) vs $1.0M ($0.06) in Q4 2020.
- Full-year 2021 revenue $27.0M (+182%); diluted EPS $0.25 vs loss of $0.42 in 2020.
- Shipped record 35 systems in Q4, including 3 to China; received Ministry of Health license renewal through 2026.
- Signed exclusive U.S. distribution agreement for TransDermal Infusion System for needle-less drug delivery.
- Affirms expectation for Q1 2022 continued growth and full-year 2022 profitability.

## SEC filing metadata
- accession: 0001213900-22-006461
- form_type: 8-K
- ticker: SRTS
- cik: 0001494891
- company_name: Sensus Healthcare, Inc.
- filed_at: 2022-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1494891/000121390022006461/0001213900-22-006461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1494891/000121390022006461/ea155130-8k_sensus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-006461
- JSON: https://secwatch.observer/filing/0001213900-22-006461.json
- Plain text: https://secwatch.observer/filing/0001213900-22-006461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.